FDA clears sale of patient-controlled ventilator

The US Food and Drug Administration (FDA) has given 510(K) clearance to Maquet Critical Care of Solna, Sweden, to market its Servo-i ventilator with the NAVA (Neurally Adjusted Ventilatory Assist) option. Sales of the system, which aims to treat and monitor neonatal, infant and adult patients, should begin this year. In addition, current Servo-i users can upgrade their system with NAVA.

Photo: FDA clears sale of patient-controlled ventilator

In this new approach to mechanical ventilation, to improve synchrony between patient and ventilator the patient’s own respiratory centre can control the ventilator. Signals from the brain’s respiratory control centre are transmitted through the phrenic nerve to the diaphragm, where a catheter captures the electrical activity (Edi) and feeds it to the ventilator. The ventilator responds by providing the requested level of support to the patient. As the ventilator and diaphragm work with the same signal, the coupling between the two is virtually instantaneous.

In addition to being a distinct mode of ventilation, NAVA also enables a complete evaluation of the neural respiratory control by capturing the electrical activity of the diaphragm (Edi). The Edi signal can be used as a unique monitoring tool, as it provides information on respiratory drive, volume requirements, the effects of ventilatory settings, and to gain indication for sedation and weaning.

Christer Ström, Director Ventilator Program, Maquet Critical Care, said: ‘We are proud to introduce the most progressive advancement within respiratory therapy since the introduction of mechanical ventilation 30 years ago.’
Details: www.maquet.com

01.05.2007

Related articles

Photo

Article •

Safer sleep, safer sugar

Ensuring the safety of hospitalised patients is vital – and brought under a particularly strong focus in anaesthesiology. Launched in 2010, the Helsinki Declaration provided a further boost.

Photo

News • Critical care

COVID-19: High mortality in hospital patients

Approximately one fifth of COVID-19 patients admitted to German hospitals between the end of February and mid-April died. For patients receiving ventilation, the mortality rate was 53%. For those not…

Photo

Article •

ICU-quality respiratory technology enters home care

John Power is breathing easier after agreeing to let the Philips Home Healthcare deal with the complex and competitive consumer market for medical technology.

Related products

Subscribe to Newsletter